NEW YORK (GenomeWeb) – Protea Biosciences and InSphero today said they will combine their 3D technologies into new products and services to be marketed to the pharmaceutical and biotechnology markets.

The collaboration will use Protea's proprietary LAESI direct molecular imaging platform to analyze InSphero's 3D InSight microtissues, resulting in 3D molecular profiles for tissue characterization, drug metabolism and distribution, pharmacokinetic, and toxicity applications, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.